Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05700149 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 36 → 50 locationsv6
  2. Start date: Dec 31, 2023 to Apr 11, 2024v5
  3. Study sites: 16 to 36v4
  4. Study sites: 7 to 16v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 1, 2023 to Dec 31, 2023
    • Study sites: 3 to 7
    • Study title expanded, about 10 words
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
International retrospective observational cohort study aimed to describe a molecular classification for NMZL.
Trial Details
NCT Number NCT05700149
Lead Sponsor International Extranodal Lymphoma Study Group (IELSG)
Conditions
(from sponsor)		 Nodal Marginal Zone Lymphoma
Related terms Lymphoma, B-Cell, Marginal Zone
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov